Disc Medicine (IRON) Enterprise Value (2020 - 2026)
Disc Medicine (IRON) reported Enterprise Value of -$730.2 million for Q1 2026, down 5.11% year-over-year from -$769.5 million in Q1 2025, and up 7.71% on a QoQ basis from -$791.2 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Enterprise Value data on file, last reported at -$730.2 million in Q1 2026.
- Quarterly Enterprise Value fell 5.11% year-over-year to -$730.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$730.2 million (down 5.11% YoY) and the FY2025 annual result came in at -$791.2 million, down 61.5% from the prior year.
- Enterprise Value improved to -$730.2 million in Q1 2026 per IRON's latest filing, from -$791.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$101.7 million in Q3 2022 and bottomed at -$791.2 million in Q4 2025.
- The 5-year median for Enterprise Value is -$377.6 million (2023), against an average of -$421.9 million.
- The widest annual swing landed in 2022, when Enterprise Value jumped 35.14%; it then sank 264.31% in 2023.
- Tracing IRON's Enterprise Value over 5 years: stood at -$194.6 million in 2022, then slumped by 85.18% to -$360.4 million in 2023, then sank by 35.93% to -$489.9 million in 2024, then tumbled by 61.5% to -$791.2 million in 2025, then grew by 7.71% to -$730.2 million in 2026.
- Per Business Quant, the three latest IRON Enterprise Value figures stand at -$730.2 million (Q1 2026), -$791.2 million (Q4 2025), and -$615.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -730.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -730.16 Mn |
| Dec 31, 2025 | -791.15 Mn |
| Sep 30, 2025 | -615.92 Mn |
| Jun 30, 2025 | -649.97 Mn |
| Mar 31, 2025 | -694.66 Mn |
| Dec 31, 2024 | -489.88 Mn |
| Sep 30, 2024 | -487.36 Mn |
| Jun 30, 2024 | -500.95 Mn |
| Mar 31, 2024 | -342.60 Mn |
| Dec 31, 2023 | -360.38 Mn |
| Sep 30, 2023 | -370.50 Mn |
| Jun 30, 2023 | -377.60 Mn |
| Mar 31, 2023 | -236.40 Mn |
| Dec 31, 2022 | -194.61 Mn |
| Sep 30, 2022 | -101.70 Mn |
| Jun 30, 2022 | -108.66 Mn |
| Mar 31, 2022 | -119.39 Mn |
| Dec 31, 2021 | -88.26 Mn |
| Sep 30, 2021 | -150.07 Mn |
| Jun 30, 2021 | -166.59 Mn |
| Mar 31, 2021 | -184.06 Mn |
| Dec 31, 2020 | -4.50 Mn |
| Sep 30, 2020 | -1.44 Mn |